| Cosentyx (secukinumab) / Novartis |
| Not yet recruiting | 4 | 40 | Europe | Cosentyx, AIN457, Solution for injection in pre-filled syringe, Cosentyx | University Hospital Schleswig-Holstein, Novartis Pharma GmbH | moderate-to-severe psoriasis, moderate-to-severe Psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2016-003592-21: Evaluating the benefits of using secukinumab rather than standard treatments as the first systemic treatment in moderate to severe psoriasis |
|
|
| Ongoing | 4 | 148 | Europe | Secukinumab, Methotrexate 2.5mg tablets, Methotrexate 10 mg tablets, CICLOSPORIN 10mg capsule, CICLOSPORIN 25mg capsule, CICLOSPORIN 50mg capsule, CICLOSPORIN 100mg capsule, AIN457, Solution for injection in pre-filled syringe, Tablet, Capsule, COSENTYX | Novartis Pharmaceuticals UK Limited, Novartis Pharmaceuticals UK Limited | Moderate to severe plaque psoriasis, Moderate to severe plaque psoriasis. Psoriasis looks like red, raised scaly areas of skin., Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2017-004700-22: Rotation or Change of Biotherapy After TNF blocker treatment failure |
|
|
| Not yet recruiting | 4 | 300 | Europe | TNF Blocker, Solution for injection, , cosentyx | CHU SAINT-Etienne, Ministère de la santé | axial Spondyloarthritis, Spondyloarthritis, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | | | | |
2018-004734-15: EBIO - investigation of inflammatory tendon Insertion by biopsy |
|
|
| Ongoing | 4 | 10 | Europe | Cosentyx, EU/1/14/980/002; EU/1/14/980/003, EU/1/14/980/004; EU/1/14/980/005, Solution and suspension for suspension for injection in pre-filled syringe, Solution for injection in pre-filled pen, Cosentyx | Universitätsklinikum Erlangen, Novartis Pharma | Psoriatic arthritis, Psoriasis with Joint involvement, Body processes [G] - Immune system processes [G12] | | | | |
2018-004724-11: Strategy Treatments Aiming at Minimal Disease Activity (MDA) in Psoriatic Arthritis Behandelstrategiëen gericht op Minimale Ziekte Activiteit (MDA) in Artritis Psoriatica. |
|
|
| Not yet recruiting | 4 | 120 | Europe | Cosentyx, Solution for injection, Cosentyx | Erasmus Medical Center, Novartis Pharma B.V. | Oligo and polyarticular psoriatic arthritis., Moderate to severe form of joint inflammation affecting individuals with the skin disorder, psoriasis., Diseases [C] - Immune System Diseases [C20] | | | | |
2019-004230-42: Dose reduction of IL17 and IL23 inhibitors for psoriasis Dosis reductie van IL17 en IL23 remmers voor psoriasis |
|
|
| Not yet recruiting | 4 | 244 | Europe | secukinumab, ixekizumab, brodalumab, risankizumab, tildrakizumab, guselkumab, Injection, Cosentyx, Taltz, Kyntheum, Skyrizi, Ilumetri, Tremfya | Radboudumc, ZonMw, KCE | psoriasis psoriasis, psoriasis psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
| Not yet recruiting | 4 | 120 | Europe | Metotressato, Secukinumab, [n.d.], Solution for injection, COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN PENNA PRERIEMPITA - USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML) - 2 PENNE PRERIEMPITE | IRCCS ISTITUTO CLINICO HUMANITAS, Novartis Farma S.p.A., Ministero della Salute | moderate to severe plaque psoriasis psoriasi a placche da moderata a grave, psoriasis psoriasi, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT03307447: Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT). |
|
|
| Recruiting | 4 | 30 | US | Secukinumab, cosentyx | Narrows Institute for Biomedical Research, Novartis | Psoriasis Vulgaris | 09/21 | 12/21 | | |
NCT04469829: Methotrexate Versus Secukinumab Safety in Psoriasis Patients With Metabolic Syndrome |
|
|
| Not yet recruiting | 4 | 70 | Europe | Secukinumab, Methotrexate | Universita di Verona | Psoriasis, Metabolic Syndrome | 12/21 | 12/22 | | |
| Active, not recruiting | 4 | 10 | Europe | Secukinumab | University of Erlangen-Nürnberg Medical School | Psoriatic Arthritis, Enthesitis, Biopsy | 03/22 | 09/22 | | |
NCT05891964: Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care Hospital. |
|
|
| Completed | 4 | 50 | RoW | Secukinumab Injection, Cosentyx | Jinnah Postgraduate Medical Centre | Plaque Psoriasis | 06/22 | 07/22 | | |
NCT05303285: A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis |
|
|
| Recruiting | 4 | 100 | RoW | Secukinumab 300mg s.c., AIN457, Cosentyx, Secukinumab 150mg s.c. | Tongji Hospital, Wuhan Central Hospital, Wuhan Hospital of Traditional Chinese Medicine | Ankylosing Spondylitis (AS) | 08/22 | 08/22 | | |
NCT03623867: PsA Secukinumab XCT Structural Progression Study |
|
|
| Completed | 4 | 40 | RoW | Secukinumab, Cosentyx, Placebo | Chinese University of Hong Kong | Psoriatic Arthritis | 09/22 | 09/22 | | |
ChiCTR2100051667: Changes of imaging and serum cytokine levels in the treatment of active ankylosing spondylitis with secukinumab: a prospective, single-center, case-control study. |
|
|
| Not yet recruiting | 4 | 60 | | Secukinumab | the First Affiliated Hospital of Dalian Medical University; the First Affiliated Hospital of Dalian Medical University, Beijing Chen Jumei Charity Foundation | Ankylosing Spondylitis | | | | |
2022-001153-23: A study of secukinumab to evaluate maintenance of response in participants with non-radiographic axial spondyloarthritis who achieved remission Etude d’évaluation du maintien de la réponse au sécukinumab chez les patients atteints de spondylarthrite axiale non radiographique en rémission |
|
|
| Ongoing | 4 | 340 | Europe | AIN457, Solution for injection in pre-filled syringe, Cosentyx | Novartis Pharma AG, Novartis Pharma AG | Non-radiographic axial spondyloarthritis, nr-axSpA is a type of inflammatory arthritis affecting spine and pelvic joints but without the evidence of joint damage visible on x-ray, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT04996485: Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children |
|
|
| Recruiting | 4 | 50 | RoW | Secukinumab Injection, Ustekinumab Injection, Dupilumab Injection, Symptomatic therapy | National Medical Research Center for Children's Health, Russian Federation | Congenital Ichthyosis | 03/23 | 06/23 | | |
ChiCTR2200064706: Changes of immune cells and inflammatory factors in psoriasis patients treated with secukizumab |
|
|
| Recruiting | 4 | 30 | | Secukinumab | The Second Hospital of Shandong University; The Second Hospital of Shandong University, the National Natural Science Foundation of China | psoriasis | | | | |
STEPin, NCT03020199 / 2015-002423-26: Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis |
|
|
| Completed | 4 | 196 | Europe, Canada, RoW | Secukinumab, AIN457, nb-UVB, Calcipotriol, Betamethasone | Novartis Pharmaceuticals | Plaque Psoriasis | 11/21 | 06/23 | | |
| Active, not recruiting | 4 | 244 | Europe | Secukinumab, Cosentyx, Ixekizumab, Taltz, Brodalumab, Kyntheum, Guselkumab, Tremfya, Risankizumab, Skyrizi, Tildrakizumab, Ilumetri, Bimekizumab, Bimzelx | Radboud University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, Belgium Health Care Knowledge Centre, University Hospital, Ghent | Psoriasis, Psoriasis Vulgaris | 12/25 | 12/25 | | |
NCT02144857: Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis |
|
|
| Recruiting | 4 | 200 | Europe | etanercept, Enbrel, ustekinumab, Stelara, cyclosporine, Neoral, Secukinumab, Cosentyx, Apremilast, Otezla | University of Athens | Psoriasis | 09/23 | 12/23 | | |
| Completed | 4 | 82 | Europe | Venapuncture, Patient questionnaires | University Hospital, Ghent, KU Leuven, University Ghent | Psoriasis Vulgaris | 12/23 | 12/23 | | |
| Recruiting | 4 | 1000 | US | Upadacitinib, Rinvoq, Abatacept, Orencia SQ, Secukinumab, Cosentyx, Tofacitinib, Xeljanz, TNF Inhibitor, Etanercept, Certolizumab, Golimumab SQ, Adalimumab, Canakinumab Injection, Ilaris, Baricitinib, Olumiant, Ixekizumab, Taltz | Jeffrey Curtis, University of Alabama at Birmingham, University of Nebraska, University of Pennsylvania, AbbVie, Bristol-Myers Squibb, Novartis, Eli Lilly and Company, Pfizer, Illumination Health | Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis | 02/24 | 09/24 | | |
NCT04717466: Brain Changes in Psoriasis After Secukinumab Treatment |
|
|
| Active, not recruiting | 4 | 23 | US | Secukinumab | University of Miami, Novartis | Psoriasis, Healthy | 05/24 | 08/24 | | |
| Not yet recruiting | 4 | 210 | Europe | Proactive TDM-based dosing of secukinumab, Cosentyx, Proactive TDM-based dosing of ixekizumab, Taltz, Proactive TDM-based dosing of guselkumab, Tremfya | University Hospital, Ghent, Belgium Health Care Knowledge Centre | Psoriasis Vulgaris | 03/28 | 03/28 | | |
ROC-SPA, NCT03445845: Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis |
|
|
| Recruiting | 4 | 300 | Europe, RoW | Secukinumab, TNF blocker, blood specimen | Centre Hospitalier Universitaire de Saint Etienne, Ministry of Health, France | Axial Spondyloarthritis | 11/24 | 11/25 | | |
NCT05527444: The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients |
|
|
| Active, not recruiting | 4 | 100 | RoW | Secukinumab 150 mg/ml, Secukinumab, Adalimumab Ab, Adalimumab, NSAID, Thalidomide Pill | Qilu Hospital of Shandong University | Ankylosing Spondylitis | 12/24 | 12/24 | | |
NCT04535999: Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV) |
|
|
| Recruiting | 4 | 40 | US | Secukinumab Auto-Injector, Cosentyx | University of Pennsylvania, Novartis | Psoriasis | 12/25 | 12/25 | | |
| Recruiting | 4 | 715 | Europe, US, RoW | Secukinumab s.c. injection | Novartis Pharmaceuticals | Autoimmunity, Inflammation | 11/27 | 02/28 | | |
ChiCTR2400087931: Exploration of Precision Individualized Medication Regimen for Psoriasis |
|
|
| Not yet recruiting | 4 | 278 | | Secukinumab Combined with Methotrexate Group; Guselkumab Combined with Methotrexate Group; Tildrakizumab Combined with Methotrexate Group; Ustekinumab Combined with Methotrexate Group; Ixekizumab Combined with Methotrexate Group | Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, the National Key Research and Development Program of China (2023YFC2508103) | Psoriasis is a chronic inflammatory disease mediated by the immune system, influenced by both genetic and environmental factors. Clinically, it manifests as red papules or plaques with white scales. In severe cases, it can present with erythroderma or pustules, accompanied by fever and systemic pain. Besides affecting the skin, it can also cause damage to multiple organs, including nails, joints, | | | | |
NCT04239859: Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis |
|
|
| Not yet recruiting | 4 | 40 | RoW | secukinumab, Methotrexate, Cyclosporin A, Acitretin | Singapore General Hospital, Translational Immunology Institute | Plaque Psoriasis | 12/27 | 12/27 | | |
NCT05622708 / 2022-001153-23: A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission |
|
|
| Recruiting | 4 | 340 | Europe, RoW | Secukinumab, Placebo | Novartis Pharmaceuticals, Novartis Pharma AG | Non-radiographic Axial Spondyloarthritis | 04/30 | 06/30 | | |
2019-000904-14: A study to assess the efficacy and safety in patients who have been treated for at least 6 months with secukinumab or ixekizumab and have experienced a suboptimal response and then switched to risankizumab. |
|
|
| Not yet recruiting | 3/4 | 250 | Europe | Risankizumab, ABBV-066, Solution for injection in pre-filled syringe | AbbVie, AbbVie Deutschland GmbH & Co.KG, ABBVIE DEUTSCHLAND GMBH & CO. KG, AbbVie Inc | Plaque Psoriasis / Psoriasis Vulgaris, Psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
| Completed | 3 | 162 | Europe, Japan, US, RoW | Experimental : Secukinumab low dose, AIN457 low dose, Experimental: Secukinumab high dose, AIN457 high dose, Placebo Comparator: Secukinumab Placebo, AIN457 placebo, Active Comparator: Etanercept, Etanercept | Novartis Pharmaceuticals | Chronic Severe Plaque-type Psoriasis | 12/18 | 03/23 | | |
|
| Completed | 3 | 743 | Europe, Canada, US, RoW | Bimekizumab, UCB4940, Secukinumab, COSENTYX®, Placebo, PBO | UCB Biopharma SRL | Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis | 09/19 | 08/23 | | |
|
|
|
NCT03668613 / 2017-004515-39: Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis |
|
|
| Completed | 3 | 84 | Europe, US, RoW | secukinumab low dose, AIN457, secukinumab high dose | Novartis Pharmaceuticals | Moderate to Severe Chronic Plaque-type Psoriasis | 09/19 | 09/23 | | |
|
2020-001899-14: An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunosuppressive medication can be tapered without recurrence of symptoms |
|
|
| Not yet recruiting | 3 | 270 | Europe | Prednisolone p.o., Sulfasalazine, Leflunomide, Methotrexate p.o., Methotrexate s.c., Etanercept, Adalimumab, Infliximab, Abatacept s.c., Abatacept i.v., Tablet, Coated tablet, , Solution for injection, Powder for concentrate for solution for infusion, Solution for injection in pre-filled pen, Solution for injection in pre-filled syringe, Solution for injection in dose-dispenser cartridge, Prolonged-release tablet, Xeljanz 5/10mg Filmtabletten, Otezla Filmtabletten, Simponi 50mg Injektionslösung Vorgefüllter Injektor/Fertigspritze, Cimzia 200mg Injektionslösung in einem Fertigpen, Orencia Injektionslösung in einer Fertigspritze, Orencia 250mg Pulver, Cosentyx 150mg Injektionslösung in einer Fertigspritze, Taltz, Cimzia 200mg Injektionslösung in einer Fertigspritze, Cimzia 200mg Injektionslösung in einer Patrone für ein Dosiergerät, Orencia 125mg Injektionslösung im Fertigpen, Cosentyx 150mg Injektionslösung in einem Fertigpen, Stelara 45mg/90mg Injektionslösung, Xeljanz 11mg Retardtablette, Rinvoq 15 mg Retardtablette, Tremfya 100mg Injektionslösung, Skyrizi 75/150mg Injektionslösung | Universitätsklinikum Erlangen, Universitätsklinikum Erlangen | Psoriatic arthritis Psoriasisarthritis, Psoriatic arthritis Gelenkbeteiligung bei Schuppenflechte, Diseases [C] - Immune System Diseases [C20] | | | | |
2019-004246-15: Study to assess efficacy of secukinumab compared to ustekinumab in adult patients with psoriatic arthritis and previous TNFα-inhibitor treatment failure |
|
|
| Not yet recruiting | 3 | 310 | Europe | Secukinumab, Ustekinumab, AIN457, Solution for injection in pre-filled syringe, Cosentyx, Stelara | Novartis Pharma GmbH, Novartis Pharma GmbH | Psoriatic arthritis, Psoriatic arthritis, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2019-003168-37: Study in patients with plaque psoriasis with coexisting non-alcoholic fatty liver disease |
|
|
| Not yet recruiting | 3 | 90 | Europe | Secukinumab, AIN457, Solution for injection in pre-filled syringe, Cosentyx | Novartis Pharma GmbH, Novartis Pharma GmbH | plaque psoriasis with coexisting non-alcoholic fatty liver disease, plaque psoriasis with coexisting non-alcoholic fatty liver disease, Body processes [G] - Immune system processes [G12] | | | | |
2020-004809-31: Study of efficacy and safety of secukinumab 300 mg in patients with giant cell arteritis (GCA). |
|
|
| Not yet recruiting | 3 | 349 | Europe, RoW | Cosentyx, Prednisone, AIN457, Solution for injection in pre-filled syringe, Capsule, hard + tablet, Cosentyx, Prednisone | Novartis Pharma AG, NOVARTIS PHARMA AG, Novartis Pharma AG | giant cell arteritis, giant cell arteritis, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2021-001256-34: study to demonstrate the efficacy and safety of secukinumab up to 224 weeks in subjects with active peripheral spondyloarthritis (pSpA). Klinické skúšanie na zhodnotenie účinnosti a bezpečnosti sekukinumabu do 224 týždňov liečby u pacientov s aktívnou periférnou spondyloartritídou (pSpA) |
|
|
| Ongoing | 3 | 324 | Europe | Solution for injection in pre-filled syringe, Cosentyx | Novartis Pharma AG, Novartis Farmacéutica, S.A., Novartis Pharma AG | Peripheral Spondyloarthritis, Peripheral Spondyloarthritis, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
NCT04156620: Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA |
|
|
| Completed | 3 | 527 | Europe, US, RoW | Secukinumab, AIN457, Placebo | Novartis Pharmaceuticals | Ankylosing Spondylitis | 02/22 | 12/22 | | |
|
|
NCT04711902: Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo. |
|
|
| Completed | 3 | 41 | RoW | AIN457, Secukinumab, Secukinumab Placebo | Novartis Pharmaceuticals | Psoriatic Arthritis | 06/22 | 03/23 | | |
2021-002622-24: Efficacy and Safety of secukinumab in patients with new onset of giant cell arteritis who are in clinical remission |
|
|
| Not yet recruiting | 3 | 146 | Europe | Secukinumab, AIN457, Solution for injection in pre-filled syringe, Cosentyx | Novartis Pharma GmbH, Novartis Pharma GmbH | Giant Cell Arteritis, Giant Cell Arteritis, Body processes [G] - Immune system processes [G12] | | | | |
2021-005772-19: An extension clinical trial of subcutaneous secukinumab to evaluate the long-term efficacy, safety and tolerability in patients with active lupus nephritis Un estudio de extensión de secukinumab subcutáneo para evaluar la eficacia, seguridad y tolerabilidad a largo plazo en pacientes con nefritis lúpica activa. |
|
|
| Ongoing | 3 | 310 | Europe, RoW | Solution for injection in pre-filled syringe, Cosentyx | Novartis Farmacéutica, S.A., Novartis Pharma AG, Novartis Pharma AG | Lupus Nephritis Nefritis lúpica, Lupus Nephritis is an inflammation of kidneys caused by systemic lupuserythematosus, an autoimmune disease (body's immune system targetsits own body tissues) that can affect any part of the body. Nefritis lúpica:inflamación de los riñones causada por lupus eritematoso sistémico,enfermedad autoinmune (el sistema inmune ataca a los tejidos propios) que puede afectar a cualquier parte del cuerpo, Diseases [C] - Immune System Diseases [C20] | | | | |
2018-003882-32: Study in patients with active axial spondyloarthritis to assess efficacy of a treat-to-target treatment strategy with secukinumab compared to a standard-of-care treatment. |
|
|
| Not yet recruiting | 3 | 300 | Europe | Secukinumab, Adalimumab, AIN457, GP2017, Solution for injection in pre-filled syringe, Cosentyx, Hyrimoz | Novartis Pharma GmbH, Novartis Pharma GmbH, Novartis Pharma S.A.S | Active axial spondyloarthritis (axSpA), Active axial spondyloarthritis (axSpA), Body processes [G] - Immune system processes [G12] | | | | |
2022-001516-26: Study of efficacy and safety and of AIN457/secukinumab in patients with rotator cuff tendinopathy |
|
|
| Not yet recruiting | 3 | 430 | Europe | Secukinumab, AIN457, Solution for injection in pre-filled syringe, Cosentyx | Novartis Pharma GmbH, Novartis Pharma GmbH | Rotator cuff tendinopathy, Rotator cuff tendinopathy, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2022-001770-59: Comparison of the efficacy and safety between two study drugs in skin disease patients |
|
|
| Not yet recruiting | 3 | 500 | Europe | Recombinant human monoclonal IgG1 antibody, Cosentyx 150 mg solution for injection in pre-filled syringe, BAT2306, NA, Solution for injection in pre-filled syringe, Cosentyx® | Bio-Thera Solutions, Ltd., Bio-Thera Solutions, Ltd. | Moderate to Severe Plaque Psoriasis, It is an autoimmune diseas characterized by raised areas of abnormal skin. These areas are red, or purple on some people with darker skin, dry, itchy, and scaly., Diseases [C] - Immune System Diseases [C20] | | | | |
2019-001177-90: Study to demonstrate the efficacy, safety and tolerability of an intravenous (i.v.) regimen of secukinumab compared to placebo in subjects with active axSpA |
|
|
| Not yet recruiting | 3 | 500 | Europe, RoW | Secukinumab, AIN457, Concentrate for solution for infusion | Novartis Pharma AG, Novartis Pharma AG | Axial Spondyloarthritis, Axial Spondyloarthritis, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2020-001611-24: Study of efficacy and safety of secukinumab in adult patients with active, moderate to severe thyroid eye disease |
|
|
| Not yet recruiting | 3 | 70 | Europe | Secukinumab, AIN457, Solution for injection in pre-filled syringe, Cosentyx | Novartis Pharma GmbH, Novartis Pharma GmbH | Active, moderate to severe thyroid eye disease, Thyroid eye disease, Diseases [C] - Eye Diseases [C11] | | | | |
ORBIT, NCT04737330: A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) |
|
|
| Terminated | 3 | 28 | Europe | Secukinumab, AIN457, Placebo | Novartis Pharmaceuticals | Thyroid Eye Disease, Graves Orbitopathy | 05/23 | 05/23 | | |
NCT05232864 / 2021-005772-19: Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis |
|
|
| Terminated | 3 | 31 | Europe, Japan, RoW | Secukinumab, AIN457 | Novartis Pharmaceuticals, Novartis Pharma AG | Lupus Nephritis | 08/23 | 08/23 | | |
| Terminated | 3 | 275 | Europe, Canada, Japan, US, RoW | secukinumab, AIN457 | Novartis Pharmaceuticals | Lupus Nephritis | 09/23 | 09/23 | | |
AgAIN, NCT04632927: Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment |
|
|
| Active, not recruiting | 3 | 119 | Europe | Secukinumab, AIN457, Ustekinumab | Novartis Pharmaceuticals | Psoriatic Arthritis | 10/24 | 10/24 | | |
NCT04179175 / 2019-003230-17: Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa |
|
|
| Active, not recruiting | 3 | 701 | Europe, Canada, Japan, US, RoW | secukinumab, AIN457 | Novartis Pharmaceuticals | Hidradenitis Suppurativa | 05/23 | 07/26 | | |
| Recruiting | 3 | 300 | Europe, Japan, US, RoW | Secukinumab | Novartis Pharmaceuticals | Polymyalgia Rheumatica | 06/28 | 07/28 | | |
NCT05377944: Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients |
|
|
| Active, not recruiting | 3 | 502 | RoW | BAT2306, Recombinant human monoclonal antibody against IL-17A, EU-approved Cosentyx, secukinumab injection | Bio-Thera Solutions | Plaque Psoriasis | 07/24 | 12/24 | | |
NCT06398652: Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 3 | 336 | RoW | CMAB015, Secukinumab, Cosentyx | Taizhou Mabtech Pharmaceutical Co.,Ltd | Psoriasis | 05/25 | 12/25 | | |
NCT04732117: Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis |
|
|
| Active, not recruiting | 3 | 138 | RoW | Secukinumab, AIN457, Placebo, AIN457 Placebo | Novartis Pharmaceuticals | Non-radiographic Axial Spondyloarthritis | 04/24 | 02/25 | | |
NCT03769168 / 2018-002521-30: An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA) |
|
|
| Active, not recruiting | 3 | 55 | Europe, US, RoW | AIN457, Secukinumab | Novartis Pharmaceuticals | Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis | 10/24 | 11/24 | | |
|
NCT04610476: Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis |
|
|
| Recruiting | 3 | 270 | Europe | Prednisolone, Prednisolone generic drugs, Sulfasalazine, Azulfidine, Leflunomide, Arava, Methotrexate, Lantarel, Metex, Tofacitinib, Xeljanz, Apremilast, Otezla, Etanercept, Enbrel, Erelzi, Benepali, Adalimumab, Humira, Amgevita, Imraldi, Hyrimoz, Infliximab, Remicade, Zessly, Inflectra, Certolizumab pegol, Cimzia, Golimumab, Simponi, Abatacept, Orencia, Secukinumab, Cosentyx, Ixekizumab, Taltz, Ustekinumab, Stelara | University of Erlangen-Nürnberg Medical School | Psoriatic Arthritis, Withdrawal, Reduction | 10/24 | 10/25 | | |
NCT05722522: Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy |
|
|
| Active, not recruiting | 3 | 34 | Europe, Canada, US, RoW | Secukinumab, AIN457, Placebo | Novartis Pharmaceuticals | Rotator Cuff Tendinopathy | 10/24 | 12/24 | | |
NCT05758415: Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy |
|
|
| Active, not recruiting | 3 | 61 | Europe, US, RoW | Secukinumab, AIN457, Placebo | Novartis Pharmaceuticals | Rotator Cuff Tendinopathy | 10/24 | 12/24 | | |
GCAptAIN, NCT04930094: Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA) |
|
|
| Active, not recruiting | 3 | 354 | Europe, Canada, US, RoW | Secukinumab 300 mg, AIN457, Placebo, Placebo Comparator, Secukinumab 150 mg | Novartis Pharmaceuticals | Giant Cell Arteritis (GCA) | 04/25 | 07/27 | | |
| Recruiting | 3 | 918 | RoW | LZM012, Secukinumab | Livzon Pharmaceutical Group Inc. | Psoriasis | 04/25 | 06/25 | | |
UnchAIN, NCT05569174: Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy |
|
|
| Active, not recruiting | 3 | 62 | Europe | secukinumab, AIN457, Placebo | Novartis Pharmaceuticals | Tendinopathy | 12/24 | 12/24 | | |
| Not yet recruiting | 3 | 20 | | Secukinumab 300mg subcutaneous injection at weeks 0, 1, 2, 3, 4, 8, 12, 16 | The Second Affiliated Hospital of Xi'an Jiaotong University; The Second Affiliated Hospital of Xi'an Jiaotong University, Bethune Charitable Foundation | generalized pustular psoriasis | | | | |
GigAINt, NCT05380453: Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission |
|
|
| Recruiting | 3 | 146 | Europe | Secukinumab 300 mg, s.c., Cosentyx, AIN457, Placebo to match Secukinumab, s.c. | Novartis Pharmaceuticals | Giant Cell Arteritis | 02/26 | 07/26 | | |
REPLENISH, NCT05767034: Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) |
|
|
| Active, not recruiting | 3 | 360 | Europe, Canada, Japan, US, RoW | Secukinumab 300 mg, AIN457, Secukinumab 150 mg, Placebo to secukinumab | Novartis Pharmaceuticals | Polymyalgia Rheumatica | 09/25 | 02/26 | | |
2015-000762-65: Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosu |
|
|
| Ongoing | 2/3 | 7 | Europe | Cosentyx, EU/1/14/980/002; EU/1/14/980/003, Solution and suspension for suspension for injection in pre-filled syringe, Cosentyx® | Technische Universität München, School of Medicine, represented by Dean, Novartis Pharmaceuticals AG | Pyoderma gangrenosum is an autoinflammatory disease, characterized by relapsing, painful ulcers of the skin. Treatment of PG is difficult. Patients suffer from long hospitalization, pain and reduced life quality. New therapeutic strategies are needed. Immunohistological staining show a high amount of IL-17 in PG. IL-17+ immune cells were located in proximity to cellular damage, indicating an involvement in the pathogenesis. Targeting IL-17 with neutralizing IL-17 antibodies seems promising., Pyoderma gangrenosum is an autoinflammatory disease. It is difficut to treat. Treatment with a new drug against IL17 seems promising., Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2017-000519-18: PIMOC : Personalized targeted therapies in inflammatory complex multi organ disease Personnalisation des traitements de Pathologies Inflammatoires Multi Organes Complexes : PIMOC |
|
|
| Not yet recruiting | 2 | 32 | Europe | SECUKINUMAB, ADALIMUMAB, ANAKINRA, RITUXIMAB, TOCILIZUMAB, USTEKINUMAB, Solution for injection, Solution for infusion | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), DGOS | Patients presenting inflammatory non classified disease targeting at least 2 organs involvement: skin, lymph nodes, hemopoietic system, joints, digestive tract. The disease has been resistant to at least two prior lines of treatment. Patient(e) présentant une maladie inflammatoire mal classée, impliquant au moins deux organes dont au moins la peau, et un des suivants : ganglions lymphatiques, système hématopoïétique, articulations, appareil digestif. La maladie a été résistante à au moins deux lignes de traitement., Patients presenting inflammatory non classified disease, resistant to prior treatment patients présentant une maladie inflammatoire non classée, sévère et résistante, Diseases [C] - Immune System Diseases [C20] | | | | |
2018-001048-70: Comparison of secukinumab versus guselkumab in clearing psoriatic plaques refractory to ustekinumab |
|
|
| Not yet recruiting | 2 | 40 | Europe | Secukinumab, Tremfya, AIN457, Solution for injection in pre-filled syringe, Solution for injection, Cosentyx, Tremfya | Novartis Pharma AG, Novartis Pharma AG | Plaque Psoriasis, Psoriasis looks like red, raised scaly areas of the skin, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2019-003588-24: Study of efficacy and safety of secukinumab 300 mg in adult patients with biopsy-proven forms of lichen planus |
|
|
| Not yet recruiting | 2 | 108 | Europe | Cosentyx, AIN457, Solution for injection in pre-filled syringe, Cosentyx | Novartis Pharma AG, Novartis Pharma AG | Lichen planus, Lichen Planus, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
ChiCTR2100041703: Half dose secukinumab combined with methotrexate in the treatment of moderate to severe plaque psoriasis: a two-stage exploratory clinical study |
|
|
| Recruiting | 2 | 98 | | half dose Secukinumab + methotrexate | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sun Yat-sen Memorial Hospital of Sun Yat-sen University | Plaque psoriasis | | | | |
| Recruiting | 2 | 32 | Europe | Kineret, Humira, Stelara, Cosentyx, Roactemra, Rituximab | Assistance Publique - Hôpitaux de Paris | Inflammatory Disease, Autoimmune Diseases | 11/25 | 11/25 | | |
NCT04298320: A Trial of SHR-1210 in Combination With AIN457 in Patients With MSS CRC（SHR-1210-AIN457） |
|
|
| Not yet recruiting | 1/2 | 40 | NA | SHR-1210, AIN 457 | Yanqiao Zhang | Colorectal Cancer | 02/22 | 02/23 | | |
NCT04967950: An Efficacy Study of Secukinumab In Enthesitis of Psoriatic Arthritis Patients |
|
|
| Recruiting | 1 | 60 | RoW | Secukinumab 300 MG, Secukinumab 150 MG, Methotrexate | Peking Union Medical College Hospital | Psoriatic Arthritis | 10/22 | 12/22 | | |
NCT04711343: Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects |
|
|
| Completed | 1 | 216 | RoW | BAT2306, Cosentyx (US-licensed), Secukinumab, Cosentyx (EU-licensed) | Bio-Thera Solutions | Psoriasis | 05/23 | 06/23 | | |
NCT06126718: Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Subjects |
|
|
| Not yet recruiting | 1 | 88 | NA | BR201, Cosentyx（Secukinumab ） | BioRay Pharmaceutical Co., Ltd. | Psoriasis | 06/24 | 08/24 | | |
ChiCTR2300067882: Phase I randomized, double-blind, parallel-controlled, single-dose pharmacokinetic, safety and immunogenicity study of CMAB015 injection versus Cosentyx in healthy Chinese male subjects |
|
|
| Not yet recruiting | 1 | 130 | | CMAB015 injection (dosage 1) ;Cosentyx (dosage 2) | The Second Hospital of Anhui Medical University; Taizhou Mabtech Pharmaceutical Co., LTD., Taizhou Mabtech Pharmaceutical Co., LTD. | Psoriasis | | | | |
NCT05734482: Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers |
|
|
| Completed | 1 | 130 | RoW | Secukinumab | Taizhou Mabtech Pharmaceutical Co.,Ltd | Psoriasis | 07/23 | 07/23 | | |
NCT06130540: Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR |
|
|
| Recruiting | 1 | 60 | Europe, US | Secukinumab, AIN457 | Novartis Pharmaceuticals | Giant Cell Arteritis, Polymyalgia Rheumatica | 06/25 | 07/25 | | |
NCT06391996: Biologic Therapy for Generalized Pustular Psoriasis |
|
|
| Completed | N/A | 65 | RoW | After exclusion of relevant contraindications, participants received subcutaneous ustekinumab/secukinumab therapy., The investigators collected participants' saliva for genotyping. | Chao Ji | Generalized Pustular Psoriasis | 12/22 | 12/23 | | |
ChiCTR1900028064: Efficacy and safety of Secukinumab in the treatment of patients with synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome |
|
|
| Not yet recruiting | N/A | 15 | | Secukinumab 150mg subcutaneous once weekly for 4 weeks (at baseline, Weeks 1, 2, 3, and 4) and every 4 weeks thereafter up to Week 16 | Peking Union Medical College Hospital; Peking Union Medical College Hospital, None | Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome | | | | |
ChiCTR2200057318: Secukinumab versus tumor necrosis factor inhibitors for refractory active Takayasu’s arteritis |
|
|
| Completed | N/A | 53 | | Secukinumab ;Tumor necrosis factor inhibitor | Peking Union Medical College Hospital; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS) (2021-I2M-1-005) | Takayasu's arteritis | | | | |
NCT05787236: A Study of Moderate-to-severe Plaque Psoriasis Patients Response to Secukinumab Treatment in Real-world Setting |
|
|
| Completed | N/A | 79 | RoW | | Novartis Pharmaceuticals | Moderate-to-severe Plaque Psoriasis | 03/22 | 03/22 | | |
FLYWAY, NCT06600009: Treatment Persistence of Biologics in Patients with PsA in Japan; Retrospective Cohort Study Using a Claims Database |
|
|
| Completed | N/A | 534 | Japan | Secukinumab, Adalimumab | Novartis | Psoriatic Arthritis | 08/23 | 09/23 | | |
NCT06172426: Incidence of Psoriatic Arthritis Among Psoriasis Patients Newly Initiated With Secukinumab in a US Claims Database and a UK Registry |
|
|
| Completed | N/A | 1171 | Europe | | Novartis Pharmaceuticals | Psoriatic Arthritis, Psoriasis | 12/22 | 12/22 | | |
ChiCTR2200065998: An exploratory randomized control study of secukinumab in the treatment of mildly active thyroid-related eye disease |
|
|
| Recruiting | N/A | 20 | | secukinumab ;N/A | Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine; Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, self-funded | thyroid-related eye disease | | | | |
NCT05583604: Secukinumab Global MAP Cohort for Adult Patients With Hidradenitis Suppurativa (HS) |
|
|
| Available | N/A | | NA | secukinumab, Cosentyx | Novartis Pharmaceuticals | Hidradenitis Suppurativa (HS) | | | | |
SPARROW, NCT06142357: Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis |
|
|
| Recruiting | N/A | 200 | RoW | Secukinumab, Cosentyx | Novartis Pharmaceuticals | Moderate-to-severe Plaque Psoriasis | 07/27 | 07/27 | | |
UNMASK2, NCT04894890: A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China |
|
|
| Completed | N/A | 1002 | RoW | secukinumab, Cosentyx | Novartis Pharmaceuticals | Psoriasis | 12/23 | 12/23 | | |
ChiCTR2100054703: The influence of Secukinumab treatment on psoriasis patients' gut microbiome: a prospective, open preliminary clinical study |
|
|
| Recruiting | N/A | 60 | | Secukinumab treatment ;None | The Second Affiliated Hospital of Guangzhou Medical University; The Second Affiliated Hospital of Guangzhou Medical University, None | Psoriasis | | | | |
ChiCTR2200058739: Real-world effect of traditional Chinese medicine combined with secukinumab in patients with psoriasis：protocol of a multi-center cohort study |
|
|
| Not yet recruiting | N/A | 540 | | Traditional Chinese Medicine Treatment ;Scrooge Uzumab Injection | Beijing Hospital of Traditional Chinese Medicine; Beijing Hospital of Traditional Chinese Medicine, Beijing Municipal Administration of Hospitals | psoriasis | | | | |
ChiCTR2400082361: Clinical and dermatoscopic changes in patients with moderate to severe plaque psoriasis treated with Secukinumab |
|
|
| Recruiting | N/A | 32 | | None | The First People's Hospital of Jingzhou; The First People's Hospital of Jingzhou, Self-raised | Psoriasis | | | | |
SPECTRA, NCT06444087: Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation |
|
|
| Recruiting | N/A | 177 | Europe | secukinumab | Novartis Pharmaceuticals | Hidradenitis Suppurativa | 03/27 | 03/27 | | |
ANIMA-R, NCT06517732: Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation |
|
|
| Recruiting | N/A | 300 | RoW | Secukinumab | Novartis Pharmaceuticals | Hidradenitis Suppurativa | 06/26 | 06/26 | | |
NCT05215561: Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP |
|
|
| Active, not recruiting | N/A | 36 | Japan | Cosentyx | Novartis Pharmaceuticals | Psoriasis Vulgaris, Psoriatic Arthritis, Pustular Psoriasis | 09/24 | 09/24 | | |
| Recruiting | N/A | 10000 | RoW | Biologic or targeted synthetic DMARD, etanercept, adalimumab, infliximab, golimumab, tocilizumab, abatacept, rituximab, ustekinumab, secukinumab, ixekizumab, or biosimilars, tofacitinib, baricitinib, upadacitinib | Seoul National University Hospital | Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis | 12/29 | 06/30 | | |
PROMPT, NCT05155098: 2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis |
|
|
| Active, not recruiting | N/A | 127 | RoW | secukinumab | Novartis Pharmaceuticals | Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis | 02/25 | 02/25 | | |
NCT05388916: A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China |
|
|
| Active, not recruiting | N/A | 42 | RoW | Cosentyx | Novartis Pharmaceuticals | Moderate to Severe Chronic Plaque Psoriasis | 04/25 | 04/25 | | |